8-K: Tharimmune Enters At-the-Market Offering Agreement to Sell Common Stock

Tharimmune, Inc. has entered into an At-the-Market Offering Agreement with Rodman & Renshaw LLC to potentially sell shares of its common stock.

Summary

• Tharimmune, Inc. has established an At-the-Market (ATM) offering agreement with Rodman & Renshaw LLC.
• Under this agreement, Tharimmune may sell shares of its common stock through Rodman & Renshaw, acting as a sales agent.
• Sales will be made at prevailing market prices, either directly on the Nasdaq or through other trading venues.
• Rodman & Renshaw will receive a 3.0% commission on the gross proceeds from any shares sold.
• The company is not obligated to sell any specific number of shares and the offering can be terminated according to the agreement's terms.
• The offering is being conducted under an existing shelf registration statement on Form S-3, which was declared effective on March 24, 2023.
• A prospectus supplement related to this offering was dated June 7, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the ATM offering provides financial flexibility, it also introduces the risk of dilution. The agreement itself is a standard financial transaction.

Positives

• The ATM agreement provides Tharimmune with a flexible way to raise capital.
• The company can sell shares at market prices, potentially maximizing proceeds.
• The company is not obligated to sell shares, allowing them to control the timing and amount of any capital raise.
• The offering is conducted under an existing shelf registration, streamlining the process.

Negatives

• The 3.0% commission will reduce the net proceeds received by the company.
• The potential sale of shares could dilute existing shareholders' ownership.
• There is no guarantee that the company will be able to sell all the shares it intends to.

Risks

• The company's stock price could be negatively impacted by the potential increase in the number of shares available.
• Market conditions could make it difficult to sell shares at desired prices.
• The company may not be able to raise the desired amount of capital through this offering.

Future Outlook

The company may sell shares of its common stock from time to time through the manager, as the company's sales agent, but is not obligated to sell any shares.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital. This allows companies to take advantage of market conditions and raise funds as needed without the need for a large, single offering.

Comparison to Industry Standards

• The 3% commission is within the typical range for ATM offerings.
• Many biotech companies use ATM offerings to fund ongoing research and development.
• The use of a shelf registration statement is standard practice for these types of offerings.
• Comparable companies that have used ATM offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if shares are sold.
• The company may have more capital to fund operations and growth.
• The company's stock price could be affected by the offering.

Next Steps

• Tharimmune may begin selling shares of its common stock through Rodman & Renshaw.
• The company will monitor market conditions to determine the timing and amount of any sales.
• The company will file any necessary prospectus supplements related to the sales.

Key Dates

Keywords

At-the-Market Offering, ATM, Common Stock, Rodman & Renshaw, Capital Raise, Share Dilution, Securities Offering, Nasdaq